CN102421451B - 苯达莫司汀环多糖组合物 - Google Patents

苯达莫司汀环多糖组合物 Download PDF

Info

Publication number
CN102421451B
CN102421451B CN2010800183017A CN201080018301A CN102421451B CN 102421451 B CN102421451 B CN 102421451B CN 2010800183017 A CN2010800183017 A CN 2010800183017A CN 201080018301 A CN201080018301 A CN 201080018301A CN 102421451 B CN102421451 B CN 102421451B
Authority
CN
China
Prior art keywords
bendamustine
composition
sbecd
cyclodextrin
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2010800183017A
Other languages
English (en)
Chinese (zh)
Other versions
CN102421451A (zh
Inventor
T·波佩克
K·帕特勒
V·艾拉霍夫
G·皮奇纳斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Softto Kimmel Pharmaceutical Co
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102421451(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of CN102421451A publication Critical patent/CN102421451A/zh
Application granted granted Critical
Publication of CN102421451B publication Critical patent/CN102421451B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800183017A 2009-02-25 2010-02-24 苯达莫司汀环多糖组合物 Active CN102421451B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US20854109P 2009-02-25 2009-02-25
US61/208,541 2009-02-25
US26994409P 2009-07-01 2009-07-01
US61/269,944 2009-07-01
US27136409P 2009-07-20 2009-07-20
US61/271,364 2009-07-20
US27929309P 2009-10-19 2009-10-19
US61/279,293 2009-10-19
US12/711,979 2010-02-24
PCT/IB2010/000502 WO2010097700A1 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions
US12/711,979 US8436032B2 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012104076231A Division CN102935080A (zh) 2009-02-25 2010-02-24 苯达莫司汀环多糖组合物

Publications (2)

Publication Number Publication Date
CN102421451A CN102421451A (zh) 2012-04-18
CN102421451B true CN102421451B (zh) 2013-11-06

Family

ID=42631521

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800183017A Active CN102421451B (zh) 2009-02-25 2010-02-24 苯达莫司汀环多糖组合物
CN2012104076231A Pending CN102935080A (zh) 2009-02-25 2010-02-24 苯达莫司汀环多糖组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012104076231A Pending CN102935080A (zh) 2009-02-25 2010-02-24 苯达莫司汀环多糖组合物

Country Status (12)

Country Link
US (2) US8436032B2 (enExample)
EP (2) EP2400987B1 (enExample)
JP (1) JP5654498B2 (enExample)
KR (1) KR101798951B1 (enExample)
CN (2) CN102421451B (enExample)
AU (1) AU2010217297A1 (enExample)
CA (1) CA2753641C (enExample)
ES (2) ES2525257T3 (enExample)
HU (1) HUE038234T2 (enExample)
NO (1) NO2792369T3 (enExample)
RU (2) RU2591804C2 (enExample)
WO (1) WO2010097700A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
DK3158991T3 (da) 2010-01-28 2021-06-14 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
HUE037575T2 (hu) * 2011-09-18 2018-09-28 Euro Celtique Sa Gyógyászati kompozíció, amely tartalmaz egy HDAC (hiszton deacetiláz) inhibitort és egy ciklopoliszacharidot
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
ES2943668T3 (es) 2012-03-20 2023-06-15 Eagle Pharmaceuticals Inc Composiciones líquidas de bendamustina para su uso en un método para tratar afecciones que responden a la bendamustina en pacientes que requieren volúmenes reducidos para administración
HUE064884T2 (hu) * 2012-03-20 2024-04-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelések
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2014085668A1 (en) * 2012-11-30 2014-06-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2015031198A2 (en) * 2013-08-27 2015-03-05 Voudouris Vasilios Bendamustine pharmaceutical compositions
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
MX2020003511A (es) * 2017-10-05 2020-07-22 Tube Pharmaceuticals Gmbh Formulaciones orales de bendamustina.
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma
CN111557904A (zh) * 2020-04-09 2020-08-21 比卡生物科技（广州）有限公司 苯达莫司汀组合物及其用途
EP4134068A4 (en) * 2020-04-09 2024-02-07 Bika Biotechnology (Guangzhou) Co., Ltd. Bendamustine composition and use thereof
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065392A2 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
WO2006076620A3 (en) * 2005-01-14 2006-12-28 Cephalon Inc Bendamustine pharmaceutical compositions for lyophilisation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
AU5004196A (en) * 1995-03-10 1996-10-02 Boehringer Mannheim Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
DE59607089D1 (de) * 1995-03-10 2001-07-19 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
AU2003224099B2 (en) 2002-04-19 2006-11-09 Novartis Ag Novel biomaterials, their preparation and use
KR20050090430A (ko) * 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
RU2390330C2 (ru) * 2003-12-31 2010-05-27 Сайдекс, Инк. Ингаляционная препаративная форма, содержащая простой сульфоалкиловый эфир гамма-циклодекстрина и кортикостероид
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
CA2569137A1 (en) * 2004-06-07 2005-12-22 Nastech Pharmaceutical Company Inc. Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
NZ553024A (en) * 2004-08-03 2009-11-27 Royal College Of Surgeons Ie Phenytoin formulations, and uses thereof in wound healing
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Ｆｇｆ−２０の調合物、生成方法および使用
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
JP5053101B2 (ja) * 2005-01-28 2012-10-17 ブリガム ヤング ユニヴァーシティー ＣＤ１ｄ−拘束ＮＫＴ細胞の細菌糖脂質による活性化
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1846685A (zh) 2006-01-25 2006-10-18 济南帅华医药科技有限公司 含苯达莫司汀和其增效剂的缓释注射剂
JP2010509363A (ja) 2006-11-08 2010-03-25 ノババックス，インコーポレイテッド 固体剤形の多相医薬組成物の製造方法
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8372834B2 (en) * 2007-03-02 2013-02-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
CN101219113A (zh) 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
CN101606934B (zh) * 2009-07-27 2011-09-28 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065392A2 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
WO2006076620A3 (en) * 2005-01-14 2006-12-28 Cephalon Inc Bendamustine pharmaceutical compositions for lyophilisation

Also Published As

Publication number Publication date
ES2675620T3 (es) 2018-07-11
EP2400987A1 (en) 2012-01-04
CN102935080A (zh) 2013-02-20
KR101798951B1 (ko) 2017-11-20
RU2016124871A3 (enExample) 2019-11-11
EP2400987B1 (en) 2014-09-03
RU2011138844A (ru) 2013-04-10
EP2792369B1 (en) 2018-04-18
CA2753641A1 (en) 2010-09-02
US8436032B2 (en) 2013-05-07
RU2734236C2 (ru) 2020-10-13
US8703964B2 (en) 2014-04-22
JP5654498B2 (ja) 2015-01-14
US20130190372A1 (en) 2013-07-25
EP2400987A4 (en) 2012-08-22
WO2010097700A1 (en) 2010-09-02
CA2753641C (en) 2014-09-16
KR20120015294A (ko) 2012-02-21
RU2591804C2 (ru) 2016-07-20
CN102421451A (zh) 2012-04-18
US20100216858A1 (en) 2010-08-26
RU2016124871A (ru) 2018-12-04
AU2010217297A1 (en) 2011-10-20
NO2792369T3 (enExample) 2018-09-15
ES2525257T3 (es) 2014-12-19
EP2792369A1 (en) 2014-10-22
HUE038234T2 (hu) 2018-10-29
JP2012519657A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
CN102421451B (zh) 苯达莫司汀环多糖组合物
US20220265829A1 (en) Formulations of bendamustine
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
CN103998046A (zh) 包含环糊精和疏水性药物的可注射药物组合物的防腐方法
CA2522115A1 (en) A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid
CN102958528A (zh) 取代β-环糊精稳定的泊沙康唑静脉输注液制剂
AU2019219792A1 (en) Bendamustine anionic-cationic cyclopolysaccharide compositions
US20110207764A1 (en) Cyclopolysaccharide compositions
EP3003265A1 (en) Parenteral formulation of triazole antifungal agent and method for preparation thereof
WO2014108918A2 (en) An injectable antifungal formulation
WO2021090183A1 (en) Liquid melphalan composition
HK1168556A (en) Bendamustine cyclopolysaccharide compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168556

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20170714

Address after: Quebec

Patentee after: Softto Kimmel pharmaceutical company

Address before: Quebec

Patentee before: Supratek Pharma Inc.

TR01 Transfer of patent right
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1168556

Country of ref document: HK